Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study.

Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. Int J Hematol. 2020 May 25;: Authors: Jung J, Choi YS, Lee JH, Lee WS, Kim SH, Park Y, Lee SS, Do YR, Jo JC, Lee JJ, Kim JS, Shin HJ, Shin DY, Yoon SS, Min CK, Kim K, Eom HS, Korean Multiple Myeloma Working Party (KMMWP) Abstract Autologous stem cell transplantation (ASCT) is not frequently performed for elderly patients multiple myeloma (MM) in Korea, despite its being a standardized approach for young patients. Medical records of 150 patients from 15 Korean institutions who received ASCT at age ≥ 64 years were analyzed retrospectively. Patients included had symptomatic MM, and had received their first ASCT at age ≥ 64 following induction chemotherapy. The main outcome was the response after ASCT. Overall survival (OS) and progression-free survival (PFS) were also analyzed. Median time to ASCT was 6.3 months. Complete response plus stringent complete response rate increased from 36 (24.0%) to 105 (70.0%) after ASCT, and high-quality response (≥ very good partial response) increased from 96 (64.0%) to 125 (83.3%). With a median follow-up of 32.6 months after ASCT, 5-year OS and PFS were 59.7% and 22.8%, respectively. Febrile neutropenia occurred in 43.5%, and nausea (21.3%) and stomatitis (13.2%) were common grade 3-4 non-hematologic adverse events. Of 44 deaths, disease progression (n = 23) was the most ...
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research